Lantheus (NASDAQ:LNTH) Price Target Raised to $127.00

Lantheus (NASDAQ:LNTH) had its price objective lifted by Truist Financial from $120.00 to $127.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Trading Up 2.5 %

Shares of LNTH stock opened at $93.82 on Thursday. The company has a market cap of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44. Lantheus has a 12-month low of $56.44 and a 12-month high of $126.89. The business’s fifty day simple moving average is $89.89 and its 200-day simple moving average is $96.73.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter worth about $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus during the 4th quarter worth about $27,000. Signaturefd LLC raised its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Lantheus during the 4th quarter worth about $37,000. Finally, UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.